Hims House 🚨 HIMS CEO ANDREW DUDUM JOINS THE PODCAST
Mar 27, 2025
Andrew Dudum, Founder and CEO of Hims & Hers, shares his insights on the rapid growth of his healthcare company, emphasizing the importance of consumer rights and navigating regulatory landscapes. He discusses the evolving market for GLP-1 medications and how Hims utilizes macroeconomic challenges to enhance its competitive edge. Dudum draws fascinating parallels between Hims and giants like Netflix and Amazon. He also shares a heartwarming story about his family's donut shop, George's Donuts and Merriment, in honor of his grandfather.
AI Snips
Chapters
Transcript
Episode notes
Core Business Growth
- Hims & Hers core business, excluding weight loss, shows robust growth.
- Diverse categories like men's and women's dermatology and sexual health drive this growth.
GLP-1 Legality and Personalization
- Personalized GLP-1 treatments are legally provided under the FDA's 503A exemption.
- This allows for customized dosing based on clinical need, addressing side effects and improving adherence.
Post-Shortage Transition
- Following the FDA's shortage announcement, Hims & Hers is transitioning customers off commercial GLP-1 doses.
- They offer alternatives like personalized doses, oral medications, and referrals.